20:03 , Dec 13, 2016 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A magnetic field cytometry-based method of detecting CTCs could help diagnose breast, prostate and other cancers. The method involved tagging tumor cell surface markers such as epithelial cell adhesion molecule (EpCAM) in patient...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Biocept, J&J sales and marketing update

Medicare contractor Palmetto GBA LLC may not reimburse circulating tumor cell (CTC) assays for malignant diagnoses, including the CellSearch Circulating Tumor Cell Kit from Johnson & Johnson's Veridex LLC unit and the OncoCEE-BR breast...
01:52 , Feb 20, 2014 |  BC Extra  |  Company News

Palmetto may not cover CTC assays

Medicare contractor Palmetto GBA may not reimburse circulating tumor cell (CTC) assays for malignant diagnoses, including the CellSearch Circulating Tumor Cell Kit from the Veridex LLC unit of Johnson & Johnson (NYSE:JNJ) and the OncoCEE-BR...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

CellSearch Circulating Tumor Cell Kit: Additional Phase III data

An analysis of 711 patients with metastatic castration-resistant prostate cancer (CRPC) in the double-blind, placebo-controlled, international Phase III COU-AA-301 trial of Zytiga abiraterone acetate showed that patients with >=5 CTCs as measured by...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

CellSearch Circulating Tumor Cell Kit: Clinical trial data

A double-blind, Chinese trial analyzing blood samples from 294 evaluable patients with metastatic breast cancer showed that detection of <5 CTCs at baseline as measured by Veridex LLC's CellSearch Circulating Tumor Cell Kit predicted significantly...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Company News

J&J, LabCorp sales and marketing update

Johnson & Johnson's Veridex LLC unit granted LabCorp rights to use CellSearch Circulating Tumor Cell Kit to perform circulating tumor cell (CTC) services for customers conducting clinical trials in China. Veridex markets the CellSearch...
07:00 , Jul 26, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens A detector to quantify antibody- and magnetic nanoparticle-tagged circulating tumor cells (CTCs) in whole blood A detector that...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Clinical News

CellSearch Circulating Tumor Cell Kit diagnostic data

Researchers at the University of Texas MD Anderson Cancer Center reported data from 302 chemotherapy-naïve patients with stage I-III non-metastatic operable breast cancer showing that detection of >=1 CTC as measured by Veridex LLC's...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

Aclasta: Postmarketing study started

Earlier this year, Novartis began a single-arm, open-label, German postmarketing trial to evaluate 4 mg IV zoledronic acid every 4 weeks for 3 months in about 60 castration-resistant prostate cancer (CRPC) patients with bone metastasis....
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

OnQChip diagnostic data

A double-blind trial analyzing blood samples from 30 cancer patients and 33 healthy controls showed that On-Q-ity's OnQChip had greater sensitivity with similar specificity for distinguishing cancer patients from healthy controls compared to Veridex LLC's...